Trial Profile
An observational, prospective study investigating efficacy of switching of an antiretroviral regimen to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed patients in France
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Feb 2017
Price :
$35
*
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 16 Feb 2017 New trial record
- 10 Feb 2017 Results published in the Journal of Antimicrobial Chemotherapy